Published in Pulm Circ on April 01, 2013
HIF-2α-mediated induction of pulmonary thrombospondin-1 contributes to hypoxia-driven vascular remodelling and vasoconstriction. Cardiovasc Res (2015) 1.43
Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. J Clin Invest (2014) 1.26
Upregulated copper transporters in hypoxia-induced pulmonary hypertension. PLoS One (2014) 0.84
DNA Damage and Pulmonary Hypertension. Int J Mol Sci (2016) 0.81
Role of epigenetics in pulmonary hypertension. Am J Physiol Cell Physiol (2014) 0.80
Animal Models of Pulmonary Hypertension: Matching Disease Mechanisms to Etiology of the Human Disease. J Pulm Respir Med (2014) 0.80
Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood (2016) 0.80
Inter-tissue coexpression network analysis reveals DPP4 as an important gene in heart to blood communication. Genome Med (2016) 0.78
Real-Time Three-Dimensional Echocardiography to Assess Right Ventricle Function in Patients with Pulmonary Hypertension. PLoS One (2015) 0.77
Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension. Circulation (2017) 0.76
Transforming growth factor beta 1 induced endothelin-1 release is peroxisome proliferator-activated receptor gamma dependent in A549 cells. J Inflamm (Lond) (2016) 0.76
Ligand-Independent Activation of Platelet-Derived Growth Factor Receptor β during Human Immunodeficiency Virus-Transactivator of Transcription and Cocaine-Mediated Smooth Muscle Hyperplasia. Am J Respir Cell Mol Biol (2015) 0.75
Clinical study of right ventricular longitudinal strain for assessing right ventricular dysfunction and hemodynamics in pulmonary hypertension. Medicine (Baltimore) (2016) 0.75
Follistatin-like 1 protects against hypoxia-induced pulmonary hypertension in mice. Sci Rep (2017) 0.75
Arterial Stiffness Induces Remodeling Phenotypes in Pulmonary Artery Smooth Muscle Cells via YAP/TAZ-Mediated Repression of Cyclooxygenase-2. Am J Physiol Lung Cell Mol Physiol (2017) 0.75
Identification of Biomarkers for Schistosoma-Associated Pulmonary Arterial Hypertension Based on RNA-Seq Data of Mouse Whole Lung Tissues. Lung (2017) 0.75
Loss of Lung WWOX Expression Causes Neutrophilic Inflammation. Am J Physiol Lung Cell Mol Physiol (2017) 0.75
Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev (1991) 42.38
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet (2008) 32.08
Notch signaling: cell fate control and signal integration in development. Science (1999) 28.83
Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature (2000) 19.15
The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev Biol (1999) 17.82
STATs and gene regulation. Science (1997) 16.55
Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet (2005) 15.96
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19
Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol (1997) 11.57
miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature (2009) 10.26
MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell (2007) 9.33
A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med (1996) 8.02
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res (2008) 7.53
The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell (2008) 7.26
MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem (2007) 6.88
Pulmonary arterial hypertension. N Engl J Med (2004) 6.69
miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell (2008) 6.59
Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med (2006) 6.06
Clinical classification of pulmonary hypertension. J Am Coll Cardiol (2004) 5.87
Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell (2010) 5.77
MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) tail function. Proc Natl Acad Sci U S A (2005) 5.35
Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 5.31
Regulation of arterial tone by activation of calcium-dependent potassium channels. Science (1992) 4.98
hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res (2008) 4.84
An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med (1992) 4.74
Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest (2005) 4.74
Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal (2009) 4.73
MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol (2007) 4.65
Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation (2002) 4.42
MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One (2006) 4.29
Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev (2000) 4.10
Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol (1998) 4.09
miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther (2007) 3.93
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med (2002) 3.91
Inhaled iloprost for severe pulmonary hypertension. N Engl J Med (2002) 3.90
Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol (1994) 3.83
Drosophila miR2 induces pseudo-polysomes and inhibits translation initiation. Nature (2007) 3.77
Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol (2009) 3.75
Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol (2009) 3.64
An epidemiological study of pulmonary arterial hypertension. Eur Respir J (2007) 3.60
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med (2001) 3.29
microRNAs in cancer management. Lancet Oncol (2012) 3.24
Inflammation in pulmonary arterial hypertension. Eur Respir J (2003) 3.18
MicroRNA: implications for cancer. Virchows Arch (2007) 3.17
Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation (2002) 3.08
Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev (2004) 3.00
Tadalafil therapy for pulmonary arterial hypertension. Circulation (2009) 2.98
Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood (2010) 2.80
ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest (2007) 2.78
Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med (1995) 2.76
An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest (2008) 2.71
Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med (2005) 2.69
Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 2.68
Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov (2006) 2.64
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation (2013) 2.64
Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res (2009) 2.61
Role for miR-204 in human pulmonary arterial hypertension. J Exp Med (2011) 2.60
Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation (2007) 2.60
Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res (1999) 2.59
The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem (2001) 2.59
Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest (2012) 2.59
A microRNA component of the hypoxic response. Cell Death Differ (2008) 2.59
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol (2010) 2.55
Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med (2008) 2.48
Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med (1991) 2.45
Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol (2011) 2.39
Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 2.31
Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol (2006) 2.25
Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol (2001) 2.24
Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med (1999) 2.21
Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation (2008) 2.18
Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet (2012) 2.16
Chronic hypoxia-induced upregulation of store-operated and receptor-operated Ca2+ channels in pulmonary arterial smooth muscle cells: a novel mechanism of hypoxic pulmonary hypertension. Circ Res (2004) 2.13
Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab (2008) 2.13
The right ventricle in pulmonary hypertension. Coron Artery Dis (2005) 2.03
Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn (2010) 2.00
Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. J Am Coll Cardiol (2008) 1.97
The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A (2007) 1.93
Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol (2006) 1.93
Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol (2010) 1.92
Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest (1991) 1.91
Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. Am J Pathol (2008) 1.90
Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. Proc Natl Acad Sci U S A (2006) 1.89
Increased plasma serotonin in primary pulmonary hypertension. Am J Med (1995) 1.86
Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet (2002) 1.85
down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. J Biol Chem (2011) 1.79
Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation (2006) 1.79
Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: lessons from the left heart. Eur Respir Rev (2010) 1.78
miRNAs get an early start on translational silencing. Cell (2007) 1.78
Notch3 signaling promotes the development of pulmonary arterial hypertension. Nat Med (2009) 1.77
Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet (2003) 1.76
Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med (2000) 1.71
Notch signaling represses myocardin-induced smooth muscle cell differentiation. J Biol Chem (2005) 1.71
Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med (2010) 1.69
Capacitative calcium entry and TRPC channel proteins are expressed in rat distal pulmonary arterial smooth muscle. Am J Physiol Lung Cell Mol Physiol (2003) 1.67
Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression. Am J Respir Crit Care Med (2012) 1.65
Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med (2002) 1.65
Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation (2005) 2.98
Role for miR-204 in human pulmonary arterial hypertension. J Exp Med (2011) 2.60
The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension. Sci Transl Med (2011) 1.95
Influences of spinal anesthesia on exercise tolerance in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.74
End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol (2009) 1.63
Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension. Am J Respir Crit Care Med (2014) 1.59
Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension. J Mol Med (Berl) (2011) 1.56
Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension. Thorax (2009) 1.55
Targeting cell motility in pulmonary arterial hypertension. Eur Respir J (2013) 1.47
Spirometry in primary care. Can Respir J (2013) 1.38
Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation (2011) 1.33
Air pollutant emissions from rice straw open field burning in India, Thailand and the Philippines. Environ Pollut (2009) 1.32
Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. Circulation (2009) 1.19
A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J Mol Med (Berl) (2013) 1.18
Evaluation of various empirical formulas for estimating mean pulmonary artery pressure by using systolic pulmonary artery pressure in adults. Chest (2008) 1.16
Role for DNA damage signaling in pulmonary arterial hypertension. Circulation (2013) 1.11
Attenuating endoplasmic reticulum stress as a novel therapeutic strategy in pulmonary hypertension. Circulation (2012) 1.06
Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol (2011) 1.05
STAT3 signaling in pulmonary arterial hypertension. JAKSTAT (2012) 1.04
Impact of preinduced quadriceps fatigue on exercise response in chronic obstructive pulmonary disease and healthy subjects. J Appl Physiol (1985) (2009) 1.03
Krüppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir Res (2011) 0.95
HIF-1 inhibition decreases systemic vascular remodelling diseases by promoting apoptosis through a hexokinase 2-dependent mechanism. Cardiovasc Res (2010) 0.95
Discovery of benzylidenebenzofuran-3(2H)-one (aurones) as inhibitors of tyrosinase derived from human melanocytes. J Med Chem (2006) 0.95
RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes. Arterioscler Thromb Vasc Biol (2011) 0.93
Effects of a rehabilitation program on skeletal muscle function in idiopathic pulmonary arterial hypertension. J Cardiopulm Rehabil Prev (2010) 0.92
Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline. Can Respir J (2010) 0.92
Sildenafil alters calcium signaling and vascular tone in pulmonary arteries from chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol (2004) 0.91
Responsiveness of Various Exercise-Testing Protocols to Therapeutic Interventions in COPD. Pulm Med (2013) 0.89
Assessment of daily life physical activities in pulmonary arterial hypertension. PLoS One (2011) 0.88
Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology. J Am Heart Assoc (2013) 0.88
Long-term physiological consequences of pneumonectomy. Semin Thorac Cardiovasc Surg (2011) 0.87
Walking exercise response to bronchodilation in mild COPD: a randomized trial. Respir Med (2012) 0.86
Chronic hypoxia induces nonreversible right ventricle dysfunction and dysplasia in rats. Am J Physiol Heart Circ Physiol (2004) 0.86
Combined effect of dietary supplementation with pressurized whey and exercise training in chronic obstructive pulmonary disease: a randomized, controlled, double-blind pilot study. J Med Food (2010) 0.85
Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension. Pharmacol Ther (2010) 0.85
From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension. J Mol Med (Berl) (2011) 0.84
Pioglitazone inhibits HIF-1α-dependent angiogenesis in rats by paracrine and direct effects on endothelial cells. J Mol Med (Berl) (2014) 0.84
Effect of pulmonary arterial hypertension-specific therapies on health-related quality of life: a systematic review. Chest (2014) 0.84
Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension. Curr Vasc Pharmacol (2015) 0.83
The estrogen puzzle in pulmonary arterial hypertension. Circulation (2012) 0.83
Tumor necrosis factor inhibitors as novel therapeutic tools for vascular remodeling diseases. Am J Physiol Heart Circ Physiol (2010) 0.83
MicroRNA networks in pulmonary arterial hypertension: share mechanisms with cancer? Curr Opin Oncol (2016) 0.82
Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH. Eur Respir J (2012) 0.82
Analogues of N-hydroxycinnamoylphenalkylamides as inhibitors of human melanocyte-tyrosinase. Bioorg Med Chem Lett (2006) 0.82
Pim-1: A new biomarker in pulmonary arterial hypertension. Pulm Circ (2013) 0.81
Effect of bisoprolol on respiratory function and exercise capacity in chronic obstructive pulmonary disease. Am J Cardiol (2012) 0.80
Repeatability and responsiveness of exercise tests in pulmonary arterial hypertension. Eur Respir J (2012) 0.80
Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension. Cell Mol Life Sci (2012) 0.79
Skeletal muscle proteomic signature and metabolic impairment in pulmonary hypertension. J Mol Med (Berl) (2014) 0.78
Preserved function and reduced angiogenesis potential of the quadriceps in patients with mild COPD. Respir Res (2014) 0.78
Severe and early quadriceps weakness in mechanically ventilated patients. Crit Care (2014) 0.77
Reduced heart rate variability in patients with chronic obstructive pulmonary disease independent of anticholinergic or β-agonist medications. COPD (2010) 0.77
Impaired Skeletal Muscle Oxygenation and Exercise Tolerance in Pulmonary Hypertension. Med Sci Sports Exerc (2015) 0.77
Strong linear relationship between heart rate and mean pulmonary artery pressure in exercising patients with severe precapillary pulmonary hypertension. Am J Physiol Heart Circ Physiol (2013) 0.76
The emergence of new therapeutic targets in pulmonary arterial hypertension: from now to the near future. Expert Rev Respir Med (2013) 0.76
Anti-inflammatory and immunosuppressive agents in PAH. Handb Exp Pharmacol (2013) 0.75
Framework for life cycle sustainability assessment of municipal solid waste management systems with an application to a case study in Thailand. Waste Manag Res (2012) 0.75
Farmer's lung-induced hypersensitivity pneumonitis complicated by shock. Respir Care (2011) 0.75